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Objectives: The discovery, development, and clinical exploitation of antibiotics with
a new mode of action combined with efﬁcient pulmonary drug delivery systems is
a top priority in the battle against untreatable chronic infections in cystic ﬁbrosis
(CF) patients. POL7001 is a novel Protein Epitope Mimetic (PEM) antibiotic with
potent activity against Pseudomonas aeruginosa (Pa) (Srinivas et al, Science 2010).
POL7001 showed a potent in vitro activity against a large panel of Pa CF multi-drug
resistant strains. To evaluate CF lung infections as potential clinical application, the
therapeutic efﬁcacy of POL7001 in mouse models was investigated.
Methods: Both Pa acute and chronic airway infection were established, and mice
were treated by subcutaneous (s.c.) or pulmonary administrations (i.t.). Body weight,
bacterial count and inﬂammation in lungs were evaluated at different time points.
Comparison to clinically approved antibiotics was included.
Results: High antibacterial activity of POL7001, in particular after i.t. adminis-
tration, was demonstrated. Leukocyte recruitment (in particular neutrophils) in the
airways was reduced after POL7001 i.t. administration. Pharmacokinetic studies
conﬁrmed that POL7001 reached favorable concentrations in the lung after i.t. ad-
ministration, with rather low systemic exposure.
Conclusion: The efﬁcacy of POL7001 was superior to ciproﬂoxacin, one of the
most effective clinically-approved antibiotics and used as an internal positive control
in our pre-clinical studies. Based on these promising results, POL7001 was selected
for further pre-clinical proﬁling.
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isolates of Pseudomonas aeruginosa
P. Beringer1, H. Ho1, T. Bensman1, A. Nguyen1, A. Wong-Beringer1, M. Selsted2.
1University of Southern California, Department of Pharmacy, Los Angeles, United
States; 2University of Southern California, Dept. of Pathology & Laboratory
Medicine, Keck School of Medicine, Los Angeles, United States
Objectives: The macrocyclic peptide rhesus theta defensin-1 (RTD-1) exhibits
broad-spectrum antibacterial and anti-inﬂammatory activities. The objective of this
study was to investigate the therapeutic potential of RTD-1 for treatment of CF
airway infection.
Methods: Stability was assessed by quantifying levels of unmodiﬁed RTD-1 in CF
sputum following incubation for 24h. Cytotoxicity was determined by quantifying
LDH release from CF bronchial epithelial cells (CuFi) following exposure to RTD-1
for 24h. In vitro susceptibility, time-kill, and post-antibiotic effects were determined
to characterize the antibacterial properties of RTD-1 following CLSI methods, using
modiﬁed Mueller Hinton broth and polypropylene plates.
Results: Greater than 90% of RTD-1 was recovered intact following incubation
in CF sputum. No cytotoxicity of CuFi cells was observed following exposure
to RTD-1 up to a concentration of 100 mcg/mL. Forty-six clinical strains of
P. aeruginosa including multidrug-resistant, colistin-resistant, and mucoid pheno-
types obtained from CF patients were tested. Irrespective of resistance pheno-
types, the MIC90 to RTD-1 was 4 mcg/mL (range: 1−8 mcg/mL); MBC values
ranged between 2−64 mcg/mL. Time kill data demonstrated rapid killing that was
concentration-dependent, with complete kill within 1.5h at 4x MIC, and a 2 log
decrease within 15 min at 64x MIC, but showed minimal post-antibiotic effects.
Conclusion: Our results indicate that RTD-1 holds promise for therapeutic develop-
ment in CF airway disease based on its favorable proﬁle: high stability, selectivity,
and potent antibacterial activity against multidrug-resistant P. aeruginosa isolates
from CF patients.
WS7.3 Once-daily liposomal amikacin for inhalation is noninferior
to twice-daily tobramycin inhalation solution in improving
pulmonary function in cystic ﬁbrosis patients with chronic
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Objective: Liposomal amikacin for inhalation (LAI) is a novel lipid formulation
being developed to treat chronic Pseudomonas aeruginosa (Pa) infection in cystic
ﬁbrosis (CF) patients (pts). The primary objective of the phase 3 study was to
compare the efﬁcacy and safety of once-daily LAI with twice-daily tobramycin
inhalation solution, USP (TIS).
Methods: This study was conducted in Europe and Canada (75 centers, 17
countries). Eligible pts were randomized 1:1 to LAI 590mg via eFlow® nebulizer
system or TIS 300mg via a PARI LC® PLUS nebulizer and stratiﬁed by age and
forced expiratory volume in 1 second (FEV1) percent predicted. Pts received 3
cycles of treatment (alternating 28 days on/off treatment). Pts were evaluated for
safety, tolerability, and efﬁcacy parameters: lung function, Pa sputum density, and
Cystic Fibrosis Questionnaire-Revised (CFQ-R).
Results: A total of 302 pts were randomized and 296 dosed. There were no
unexpected adverse events (AEs), and treatment-emergent AEs were consistent with
underlying CF disease. The primary endpoint was achieved; LAI was noninferior
to TIS with respect to the relative change from baseline to end of study in
FEV1. Reduction in Pa sputum density was comparable during all on-treatment
periods. Treatment Burden on the CFQ-R improved with LAI. Clinically meaningful
improvements on the CFQ-R Respiratory Symptoms score were also observed for
those on LAI.
Conclusion: LAI administered once daily is comparable to TIS administered twice
daily in improving lung function. LAI is generally safe and well tolerated. These
data will further our understanding of a new antibiotic to treat chronic Pa lung
infection in CF pts.
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We developed an online Cayston Treatment Evaluator to assess its effectiveness in
routine practice in our centres. Data was extracted for 1 year Pre Cayston [Pre] and
for up to 1 year post Cayston [Post] from 9 centres in Ireland and the UK. The
median (IQR) actual observed follow-up post Cayston (n = 113) was 45 (31.5, 52)
weeks. 51.6% female, mean (SD) age 32.8 (9.6) years, mean (SD) body mass index
21.3 (3.1) kg/m2.
The median (IQR) FEV1%predicted deteriorated from Pre 6−12 months to Pre
0−6 months (n = 113): 39.6% (29.2, 48.5) to 36.2% (25.1, 45.4), p< 0.001, but improved
from Pre 0−6 to Post 0−6 months (n = 111): 35.9% (27.5, 44.5) to 37.3% (27.3, 46.3),
p = 0.02. In subjects with complete 2 year FEV1 data (n = 76), the rate of deterioration
in median (IQR) FEV1% predicted across the 2 consecutive 6 month intervals post-
Cayston: −0.9% (−3.0, 1.0) was substantially lower than pre-Cayston −2.0% (−4.4, 0.9),
p = 0.055. Median (IQR) body weight deteriorated from Pre 6−12 to Pre 0−6 months
(n = 113): 59.2 kg (51.1, 66.9) to 58.0 kg (51.5, 67.9), p = 0.5; but increased from Pre
0−6 to Post 0−6 months (n = 112) 58.0 (51.5, 68.1) to 59.9 (53.1, 68.8), p< 0.001. Clin-
ical event rates extrapolated to the 1 year Post and compared with the observed 1 year
Pre rates signiﬁcantly decreased with the median (IQR) for hospital bed days/year:
19 (3.5, 41.5) vs. 5.5 (0.0, 34.8), p = 0.001 and for total and home IV antibiotic days
per year 55.5 (28.0, 88.5) vs. 31.7 (13, 61.9), p< 0.001 and 21.0 (0.0, 52.0) vs. 13.5
(0.0, 34.1), p< 0.001.
Our real world evaluator showed in a deteriorating cohort, the introduction of Cayston
signiﬁcantly improved lung funtion, weight, hospitalisation and exacerbation rates.
